78 related articles for article (PubMed ID: 25389712)
1. Specialized surveillance for individuals at high risk for melanoma: a cost analysis of a high-risk clinic.
Watts CG; Cust AE; Menzies SW; Coates E; Mann GJ; Morton RL
JAMA Dermatol; 2015 Feb; 151(2):178-86. PubMed ID: 25389712
[TBL] [Abstract][Full Text] [Related]
2. Cost-Effectiveness of Skin Surveillance Through a Specialized Clinic for Patients at High Risk of Melanoma.
Watts CG; Cust AE; Menzies SW; Mann GJ; Morton RL
J Clin Oncol; 2017 Jan; 35(1):63-71. PubMed ID: 28034073
[TBL] [Abstract][Full Text] [Related]
3. The economic implications of treating atherothrombotic disease in Australia, from the government perspective.
Ademi Z; Liew D; Hollingsworth B; Wolfe R; Steg GP; Bhatt DL; Reid CM;
Clin Ther; 2010 Jan; 32(1):119-32; discussion 106-7. PubMed ID: 20171418
[TBL] [Abstract][Full Text] [Related]
4. Estimated Healthcare Costs of Melanoma in Australia Over 3 Years Post-Diagnosis.
Elliott TM; Whiteman DC; Olsen CM; Gordon LG
Appl Health Econ Health Policy; 2017 Dec; 15(6):805-816. PubMed ID: 28756584
[TBL] [Abstract][Full Text] [Related]
5. A National Budget Impact Analysis of a Specialised Surveillance Programme for Individuals at Very High Risk of Melanoma in Australia.
Watts CG; Wortley S; Norris S; Menzies SW; Guitera P; Askie L; Mann GJ; Morton RL; Cust AE
Appl Health Econ Health Policy; 2018 Apr; 16(2):235-242. PubMed ID: 29305821
[TBL] [Abstract][Full Text] [Related]
6. Economic burden of melanoma in the elderly population: population-based analysis of the Surveillance, Epidemiology, and End Results (SEER)--Medicare data.
Seidler AM; Pennie ML; Veledar E; Culler SD; Chen SC
Arch Dermatol; 2010 Mar; 146(3):249-56. PubMed ID: 20231494
[TBL] [Abstract][Full Text] [Related]
7. Prospective evaluation of follow-up in melanoma patients in Germany - results of a multicentre and longitudinal study.
Livingstone E; Krajewski C; Eigentler TK; Windemuth-Kieselbach C; Benson S; Elsenbruch S; Hauschild A; Rompel R; Meiss F; Mauerer A; Kähler KC; Dippel E; Möllenhoff K; Kilian K; Mohr P; Utikal J; Schadendorf D
Eur J Cancer; 2015 Mar; 51(5):653-67. PubMed ID: 25638778
[TBL] [Abstract][Full Text] [Related]
8. The economic burden of melanoma in France: assessing healthcare use in a hospital setting.
Chevalier J; Bonastre J; Avril MF
Melanoma Res; 2008 Feb; 18(1):40-6. PubMed ID: 18227707
[TBL] [Abstract][Full Text] [Related]
9. Costs of illness for melanoma and nonmelanoma skin cancer in Denmark.
Bentzen J; Kjellberg J; Thorgaard C; Engholm G; Phillip A; Storm HH
Eur J Cancer Prev; 2013 Nov; 22(6):569-76. PubMed ID: 23542376
[TBL] [Abstract][Full Text] [Related]
10. Diagnosis and management costs of suspicious skin lesions from a population-based melanoma screening programme.
Gordon L; Youl PH; Elwood M; Janda M; Ring IT; Lowe JB; Aitken JF
J Med Screen; 2007; 14(2):98-102. PubMed ID: 17626710
[TBL] [Abstract][Full Text] [Related]
11. The Royal Flying Doctor Service primary care skin cancer clinic: a pilot program for remote Australia.
Scrace M; Margolis SA
Rural Remote Health; 2009; 9(1):1048. PubMed ID: 19239334
[TBL] [Abstract][Full Text] [Related]
12. The 3C study: coverage cost and care of type 1 diabetes in China--study design and implementation.
McGuire H; Kissimova-Skarbek K; Whiting D; Ji L
Diabetes Res Clin Pract; 2011 Nov; 94(2):307-10. PubMed ID: 22056720
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness analysis of FDG PET-CT in the management of pulmonary metastases from malignant melanoma.
Krug B; Crott R; Roch I; Lonneux M; Beguin C; Baurain JF; Pirson AS; Vander Borght T
Acta Oncol; 2010; 49(2):192-200. PubMed ID: 20059314
[TBL] [Abstract][Full Text] [Related]
14. The health burden and economic costs of cutaneous melanoma mortality by race/ethnicity-United States, 2000 to 2006.
Ekwueme DU; Guy GP; Li C; Rim SH; Parelkar P; Chen SC
J Am Acad Dermatol; 2011 Nov; 65(5 Suppl 1):S133-43. PubMed ID: 22018062
[TBL] [Abstract][Full Text] [Related]
15. Melanoma costs: a dynamic model comparing estimated overall costs of various clinical stages.
Alexandrescu DT
Dermatol Online J; 2009 Nov; 15(11):1. PubMed ID: 19951637
[TBL] [Abstract][Full Text] [Related]
16. Investment in new technology research can save future health care dollars.
Reintgen D; Albertini J; Milliotes G; Marshburn J; Cruse CW; Rapaport D; Berman C; Glass F; Fensske N; Einstein AB; Lyman G
J Fla Med Assoc; 1997 Mar; 84(3):175-81. PubMed ID: 9143169
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness of reduced follow-up in malignant melanoma.
Hengge UR; Wallerand A; Stutzki A; Kockel N
J Dtsch Dermatol Ges; 2007 Oct; 5(10):898-907. PubMed ID: 17910672
[TBL] [Abstract][Full Text] [Related]
18. Cost of providing inpatient burn care in a tertiary, teaching, hospital of North India.
Ahuja RB; Goswami P
Burns; 2013 Jun; 39(4):558-64. PubMed ID: 23523069
[TBL] [Abstract][Full Text] [Related]
19. Incidence estimate of nonmelanoma skin cancer in the United States, 2006.
Rogers HW; Weinstock MA; Harris AR; Hinckley MR; Feldman SR; Fleischer AB; Coldiron BM
Arch Dermatol; 2010 Mar; 146(3):283-7. PubMed ID: 20231499
[TBL] [Abstract][Full Text] [Related]
20. What difference a decade? The costs of psychosis in Australia in 2000 and 2010: comparative results from the first and second Australian national surveys of psychosis.
Neil AL; Carr VJ; Mihalopoulos C; Mackinnon A; Lewin TJ; Morgan VA
Aust N Z J Psychiatry; 2014 Mar; 48(3):237-48. PubMed ID: 24220136
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
